Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether darbepoetin alfa manufactured by the current "roller bottle" technology and darbepoetin alfa manufactured by a serum free process have a comparable safety profile.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Darbepoetin alfa

Criteria

Inclusion Criteria:

• Currently diagnosed with Chronic Kidney Disease, either receiving or not receiving dialysis

• Anemic

• Currently on erythropoietic therapy

• Controlled hypertension

• Clinically stable